Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs Compass Therapeutics, Inc. (CMPX)

Coherus Oncology, Inc. and Compass Therapeutics, Inc. are both Biotechnology companies. Coherus Oncology, Inc. and Compass Therapeutics, Inc. are of similar size ($165.3M and $161.5M). Compass Therapeutics, Inc. has the higher net margin (0.00% vs −259.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Compass Therapeutics, Inc. leads on 9 and Coherus Oncology, Inc. on 5.

Valuation

Metric CHRS CMPX Biotechnology median
P/E n/m n/m 8.50
P/S 3.04 n/m 9.71
P/B 2.54 0.97 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.17 0.64
EV/Sales 5.14 n/m 9.21
Earnings yield (103.00%) (46.51%) (33.15%)
Free cash flow yield (120.77%) (35.09%) (25.50%)

Profitability

Metric CHRS CMPX Biotechnology median
Gross margin 68.94% 0.00% 65.16%
Operating margin (311.56%) 0.00% 0.00%
Net margin (259.41%) 0.00% 0.00%
Free cash flow margin (365.22%) 0.00% 0.00%
Return on equity (146.27%) (56.66%) (56.36%)
Return on assets (41.90%) (47.87%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CHRS CMPX Biotechnology median
Revenue growth (TTM) 61.00% — 6.02%
EPS growth (last fiscal year) 472.00% (16.67%) 30.26%
Revenue growth, 5-year CAGR (38.41%) — 9.41%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS CMPX Biotechnology median
Debt to equity 0.61 0.00 0.00
Current ratio 1.77 11.22 4.72
Net debt to EBITDA 0.76 2.86 0.96

Dividend

Metric CHRS CMPX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CHRS CMPX Biotechnology median
Market cap 165.32m 161.49m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack